Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:approves |
gptkb:2012
gptkb:FDA |
| gptkbp:atccode |
L01 XE26
|
| gptkbp:brand |
Bosulif
|
| gptkbp:casnumber |
380843-75-4
|
| gptkbp:category |
gptkb:D
not recommended |
| gptkbp:chemical_formula |
C24 H26 Cl N5 O2
|
| gptkbp:clinical_trial |
Phase II
Phase III Phase I |
| gptkbp:clinical_use |
second-line treatment
third-line treatment |
| gptkbp:contraindication |
severe hepatic impairment
hypersensitivity to bosutinib |
| gptkbp:developed_by |
gptkb:Pfizer
|
| gptkbp:dissolved |
soluble in DMSO
slightly soluble in water soluble in methanol |
| gptkbp:dosage_form |
500 mg once daily
|
| gptkbp:drug_interactions |
CYP3 A4 inducers
CYP3 A4 inhibitors |
| gptkbp:excretion |
urine
|
| gptkbp:healthcare |
July 2012
|
| https://www.w3.org/2000/01/rdf-schema#label |
Bosutinib
|
| gptkbp:lifespan |
approximately 30 hours
|
| gptkbp:mechanism_of_action |
inhibitor of BCR-ABL and SRC family kinases
|
| gptkbp:metabolism |
primarily hepatic
|
| gptkbp:pharmacokinetics |
inhibits cell proliferation
induces apoptosis in cancer cells oral bioavailability approximately 34% |
| gptkbp:research_areas |
oncology
hematology |
| gptkbp:route_of_administration |
oral
|
| gptkbp:safety_measures |
risk of thrombosis
risk of gastrointestinal perforation monitor blood pressure risk of bleeding monitor liver function |
| gptkbp:side_effect |
fatigue
headache nausea hypertension diarrhea |
| gptkbp:targets |
gptkb:BCR-ABL_tyrosine_kinase
|
| gptkbp:type_of_care |
important for treatment efficacy
|
| gptkbp:used_for |
treatment of chronic myelogenous leukemia
|
| gptkbp:water_resistance |
BCR-ABL mutations
|
| gptkbp:weight |
469.95 g/mol
|
| gptkbp:bfsParent |
gptkb:Genzyme_Genetics
|
| gptkbp:bfsLayer |
6
|